Connect with us

Technology

High Throughput Screening (HTS) Market to Grow by USD 19.9 Billion (2024-2028), Boosted by Rising R&D Investments, with AI Redefining Market Landscape – Technavio

Published

on

NEW YORK, Jan. 31, 2025 /PRNewswire/ — Report with market evolution powered by AI – The global high throughput screening (HTS) market size is estimated to grow by USD 19.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 12.12%  during the forecast period. Rise in R and D investments is driving market growth, with a trend towards increasing focus on promotional activities. However, shortage of trained healthcare professionals  poses a challenge. Key market players include Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

High Throughput Screening (HTS) Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 12.12%

Market growth 2024-2028

USD 19.9 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

11.64

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Japan, China, Germany, and France

Key companies profiled

Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Market Driver

High-throughput screening (HTS) is a key trend in the life sciences sector, particularly in the areas of drug discovery and research for complex illnesses like cancer and neurological disorders. HTS allows for the rapid testing of large compound libraries using automated equipment such as robotic arms and microplate readers. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to analyze genomic data and chemical databases for target identification. Biotech startups and academic institutions are driving innovation in this field, with pharmaceutical corporations and research organizations collaborating to advance drug development. HTS is also used in stem cell research, toxicology, and open innovation models. HTS service providers offer instruments, software, and consumables to support this research. HTS is transforming the biopharmaceutical industry, enabling precision medicine and the repurposing of existing drugs for new indications. With advancements in technology, HTS is becoming more accessible to a wider range of organizations, including biotechnology startups and clinical trials. Despite these advancements, challenges remain, including false-positive findings and the need for specialized equipment maintenance. Overall, HTS is a vital tool in the global healthcare sector’s quest to develop new products and services for the detection and treatment of chronic diseases. 

The High Throughput Screening (HTS) market presents unique challenges for vendors due to its specialized nature and niche end-users. Brand and product visibility play a limited role in sales, and advertising and marketing are restricted. Key players in the industry recognize this issue and are promoting HTS through their websites and additional support materials. Thermo Fisher Scientific, for instance, provides explanatory documents, brochures, and interactive videos on YouTube to help end-users understand the technique better. Despite these efforts, there is a significant lack of awareness about HTS. Vendors must focus on improving their distribution networks to make these products readily available to end-users. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

High-throughput screening (HTS) is a crucial process in the biotechnology industry, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. The market for HTS is vast and diverse, with players including academic institutions, biotech startups, and pharmaceutical corporations. Challenges in this field include managing large data sets from compound libraries, dealing with false-positive findings, and maintaining specialized equipment. HTS involves the use of automation, robotics, and specialized instruments like microplate readers and high-resolution imaging systems. Data analytics is essential for making sense of the vast amounts of data generated. Machine learning and data management systems help in data organization, retrieval, integration, and storage. HTS is not just limited to pharmaceutical companies but also extends to the global healthcare sector, research organizations, and contract research organizations. Collaborative networks and HTS service providers play a significant role in driving innovation through open innovation models. HTS is also used in stem cell research, toxicology, and drug development. HTS involves various techniques like cell-based assays, lab-on-a-chip, and label-free technology. Biochemical screening and target identification are critical components of the HTS process. Drug repurposing initiatives, such as those from Relay Therapeutics, are gaining popularity in the biopharmaceutical industry due to their potential to bring new drugs to market faster and more cost-effectively. The HTS market is expected to grow significantly due to the increasing focus on precision medicine and the need for new drugs to address chronic diseases. Consumables, software, and services are essential products and services in the HTS market. The use of technology in HTS, such as automation and advanced detection techniques, is transforming the drug discovery process. Despite the challenges, the future of HTS looks promising, with advancements in technology and a growing focus on collaboration and open innovation models. The use of HTS in drug discovery and development is expected to revolutionize the way we approach complex illnesses and bring new treatments to market.In today’s fast-paced pharmaceutical and biotechnology industries, High Throughput Screening (HTS) has become a crucial tool for discovering new drugs and optimizing existing ones. However, the successful implementation of HTS relies heavily on the availability of skilled personnel. The shortage of trained professionals in this field can lead to non-compliance and improper screening of drug targets. Consequently, product failures and regulatory issues can result in significant financial losses for companies. This issue is particularly prevalent in developing countries, where the healthcare system lacks the necessary workforce to effectively utilize HTS technology. To mitigate this challenge, it is essential for organizations to invest in training and development programs for their staff, ensuring they have the necessary expertise to operate HTS equipment effectively and efficiently.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview 

This high throughput screening (HTS) market report extensively covers market segmentation by  

Application 1.1 Target identification and validation1.2 Primary and secondary screening1.3 Toxicology assessment1.4 Stem cell researchEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 Academic and research institutes2.3 CROsGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Target identification and validation-  The global high throughput screening (HTS) market is driven by the increasing need for target identification and validation in drug development. This process involves finding potential therapeutic targets for diseases or conditions without existing treatments or inadequate current options. Early and thorough target identification and validation establish a strong link to clinical trial success. Chronic diseases like cardiovascular diseases, cancer, and respiratory diseases, which have a high global prevalence, fuel the demand for new targets. Additionally, the growing pipeline for biological candidates, outsourcing from pharmaceutical companies, and regulatory agencies’ demand for accurate drug and process development details contribute to market expansion. Advanced bioinformatics tools, automated experimental designs, and AI/ML algorithms are enhancing target identification and validation, further boosting the segment’s growth. Consequently, these factors are expected to fuel the growth of the target identification and validation segment in the global high throughput screening market during the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

High-throughput screening (HTS) is a critical technology in the global healthcare sector, enabling the rapid and efficient identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, often containing hundreds of thousands to millions of compounds, which are screened against disease targets using automated systems. These systems include robotic arms, microplate readers, and high-resolution imaging systems. Data analytics plays a crucial role in HTS, with data management systems, data storage, data organization, data retrieval, data integration, and chemical databases essential for processing and interpreting the vast amounts of data generated. Academic institutions, biotech startups, research organizations, and pharmaceutical corporations all contribute to the HTS market, with open innovation models facilitating collaboration and knowledge sharing. Drug repurposing, the process of discovering new uses for existing drugs, is also a significant application of HTS. The market for HTS is expected to grow significantly due to the increasing demand for new and effective treatments for various diseases.

Market Research Overview

High Throughput Screening (HTS) is a critical technology in the life sciences sector, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, automation, and specialized equipment like robotic arms, microplate readers, and high-resolution imaging systems to screen large numbers of compounds against specific targets. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to organize, store, retrieve, integrate, and analyze genomic data and chemical databases. Collaborative networks and HTS service providers facilitate open innovation models and knowledge sharing among academic institutions, biotech startups, pharmaceutical corporations, and research organizations. Drug repurposing initiatives and biopharmaceutical industry leaders are leveraging HTS for precision medicine and target identification, while toxicology and stem cell research also benefit from this technology. The global healthcare sector continues to invest in HTS for drug discovery, clinical trials, and product development, driving the market for instruments, software, and consumables.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationTarget Identification And ValidationPrimary And Secondary ScreeningToxicology AssessmentStem Cell ResearchEnd-userPharmaceutical And Biotechnology CompaniesAcademic And Research InstitutesCROsGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/high-throughput-screening-hts-market-to-grow-by-usd-19-9-billion-2024-2028-boosted-by-rising-rd-investments-with-ai-redefining-market-landscape—technavio-302364447.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Gemtek and Dixon Advance Strategic Collaboration to Expand Optical Connectivity Business in India

Published

on

By

Combining photonic integration expertise with localized manufacturing to address growing demand for high-speed optical connectivity across Broadband, Telecom and AI Infrastructure

TAIPEI, Sept. 1, 2026 /PRNewswire/ — Gemtek Technology Co., Ltd. (“Gemtek”) and Dixon Technologies (India) Limited (“Dixon”) are advancing their strategic collaboration through their joint venture in India, expanding manufacturing and market opportunities for Optical Transceivers, BOSA (Bidirectional Optical Sub-Assembly) and other high-speed optical connectivity solutions.

The collaboration combines Gemtek’s expertise in optical communications, photonic integration and product development with Dixon’s manufacturing scale, supply-chain capabilities and market presence in India, creating a scalable platform to serve Broadband, Telecom, Cloud, Data Center and AI Infrastructure markets in India and globally.

Expanding Next-Generation Optical Connectivity

Gemtek is expanding its optical connectivity portfolio with solutions spanning 1G to 1.6T, including Optical Transceivers, SFPs, BOSA and high-speed optical connectivity solutions.

Leveraging EIC-PIC photonic integration and advanced manufacturing capabilities, Gemtek is advancing its roadmap toward 800G, 1.6T and next-generation photonic integration technologies to address growing demand for high-bandwidth and high-performance connectivity driven by AI, cloud and data center infrastructure.

Strengthening Local Manufacturing and Supply-Chain Resilience in India

The collaboration supports India’s growing focus on local manufacturing of Optical Transceivers, BOSA and other high-speed optical solutions. By combining Gemtek’s technology and product development expertise with Dixon’s local manufacturing and supply-chain capabilities, the partnership enables scalable production in India while complementing Gemtek’s global manufacturing footprint, strengthening geographic diversification and overall supply-chain resilience.

Gemtek to Showcase Optical Connectivity at IMC 2026

Gemtek will participate in India Mobile Congress (IMC) 2026, taking place October 7–10, 2026, at Yashobhoomi, New Delhi, India, Hall 2, Booth B1.

Gemtek will showcase its 1G-to-1.6T Optical Connectivity portfolio and solutions for Broadband, Telecom and AI Data Center applications, including Optical Transceivers, BOSA and next-generation high-speed optical connectivity technologies.

About Gemtek

Gemtek Technology is a global provider of networking and communications solutions across Broadband, Wi-Fi, Fiber, 5G, Optical Connectivity and AI-enabled Networking. Combining photonic integration, product innovation and advanced manufacturing capabilities, Gemtek continues to expand its high-speed optical connectivity technologies and solutions.

About Dixon

Dixon Technologies (India) Limited is a leading Indian design-focused and manufacturing company serving consumer electronics, telecommunications, IT hardware and other technology sectors, with extensive capabilities in product design, engineering, large-scale manufacturing and supply-chain management.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/gemtek-and-dixon-advance-strategic-collaboration-to-expand-optical-connectivity-business-in-india-302865904.html

Continue Reading

Technology

Haut.AI Launches AI-Powered Hair Analysis for Beauty Brands Worldwide

Published

on

By

New technology turns a smartphone selfie and short questionnaire into personalized hair profiles and product recommendations for beauty brands and retailers

NEW YORK, Sept. 1, 2026 /PRNewswire/ — Haut.AI, a SaaS technology company specializing in AI-powered skin intelligence and personalized skincare, today announced the commercial launch of Hair Analysis, a B2B AI-powered hair assessment technology that enables beauty brands and retailers to deliver personalized haircare recommendations through digital commerce experiences.

Hair Analysis combines a smartphone selfie with a short questionnaire to create a personalized hair profile. The technology evaluates six visible hair characteristics, combines those findings with information about a consumer’s routine and concerns and connects the resulting profile with relevant products from a brand’s catalog. Hair Analysis is now commercially available to beauty and retail companies worldwide.

The launch expands Haut.AI’s personalization platform beyond skincare, allowing brands to offer AI-powered skin and hair experiences through the same SaaS infrastructure.

“Haircare has faced a longstanding personalization challenge: hair is highly individual, yet product discovery still often relies on broad categories and trial and error,” said Anastasia Georgievskaya, CEO & Co-founder of Haut.AI. “Hair Analysis addresses that gap by combining visual assessment with consumer-provided insights to help brands connect people with more relevant products.”

How Haut.AI Hair Analysis Works

Consumers can complete a Hair Analysis assessment in less than one minute. After answering a short questionnaire about their hair, styling habits and concerns, they take a smartphone selfie that is analyzed using Haut.AI’s computer-vision technology.

The system evaluates six visible characteristics:

Hair curvatureHair densityHair volumeFrizz levelHair colorColor uniformity

Those findings are combined with questionnaire responses to create a personalized hair profile. The combined inputs support recommendations across 19 hair concerns, including dryness, frizz, split ends, hair loss, chemical damage, dandruff, lack of volume and oily or greasy hair.

Hair Analysis spans 12 product categories, from shampoos and conditioners to treatments, masks, oils, and styling products.

How Hair Analysis Helps Beauty Brands Personalize Haircare

Hair Analysis is delivered through Haut.AI’s SaaS platform and can be integrated into beauty brands’ and retailers’ digital commerce experiences. Brands can manage product catalogs, configure recommendation logic, connect individual hair profiles with relevant products from their own portfolios, and access consumer insights generated from hair analysis data to better understand customer needs and preferences.

Companies already using Haut.AI for skin analysis can add hair personalization through the same platform, creating a unified technology foundation for personalized skin and hair experiences.

Hair Analysis Builds on Haut.AI’s Beauty Personalization Technology

Hair Analysis was initially co-developed with Grupo Boticário following the Brazilian beauty company’s strategic investment in Haut.AI. The collaboration combined Haut.AI’s computer-vision and AI-powered personalization capabilities with Grupo Boticário’s experience in haircare science, consumer insights and diverse hair needs. Grupo Boticário served as Haut.AI’s launch partner for the technology, which is now available to beauty brands and retailers worldwide.

“As an early partner in the development of Hair Analysis, we’ve seen firsthand how this technology can make haircare discovery intuitive for consumers,” said Gustavo Dieamant, Executive Director of R&D at Grupo Boticário. “Hair needs are incredibly diverse, and Haut.AI has developed a solution that translates that complexity into an experience that helps consumers identify products suited to their individual needs. We’re excited to see Haut.AI now bring this technology to beauty brands around the world.”

With Hair Analysis joining Haut.AI’s Face Analysis 3.0 and recently launched Body Analysis, Haut.AI now provides AI-powered personalization across face, body and hair. This broad coverage enables beauty brands, pharmacy groups and retailers with diverse product portfolios to use a unified technology platform. It helps them address a wider range of consumer needs, deliver more personalized product recommendations and create connected beauty experiences across digital and in-store channels.

Learn more about Hair Analysis, visit https://haut.ai/products/hair-analysis.

Try the Hair Analysis demo at: https://haut.ai/hair-analysis-demo.

Press images and assets can be downloaded here.

About Haut.AI

Haut.AI is a SaaS technology company at the forefront of generative AI-powered skincare personalization and skin intelligence. Founded by scientists and AI innovators, the company has built proprietary technology that turns skin data into objective, quantifiable intelligence across all skin tones and body regions. Haut.AI collaborates with leading global beauty and wellness brands, including Neutrogena, Beiersdorf, Ulta Beauty, and Grupo Boticário, enabling them to deliver science-backed, hyper-personalized skincare experiences that drive measurable consumer engagement and business impact. For more information, visit www.haut.ai.

Media contact:
Michael Tebo
Gabriel Marketing Group (for Haut.AI)
Phone: 571-835-8775
Email: michaelt@gabrielmarketing.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hautai-launches-ai-powered-hair-analysis-for-beauty-brands-worldwide-302865372.html

SOURCE Haut.AI

Continue Reading

Technology

AI is a Mirror, Not a Replacement: Bionic Artist Viktoria Modesta Challenges the Core of Human Value in the Machine Age

Published

on

By

Groundbreaking Futurist and Former MIT Media Lab Fellow Joins C. M. (Cathy) Rubin on AI for a Better World—Produced by the Planet Classroom Network—to Reframe the Emerging AI Identity Crisis for the Next Generation

NEW YORK, Sept. 1, 2026 /PRNewswire/ — As artificial intelligence shifts from a corporate automation tool into an intimate part of daily identity, a profound psychological question is emerging: If machines can replicate human intelligence, what happens to the value of human experience?

In a landmark new episode of AI For A Better World, host C. M. (Cathy) Rubin—in the acclaimed series produced by the Planet Classroom Network—sits down for an in-depth conversation with internationally recognized multimedia artist, futurist, and former MIT Media Lab Fellow Viktoria Modesta to explore how emerging technology is reshaping identity, creativity, and human agency.

“We’ve spent centuries using technology to change the world around us,” Rubin states. “But AI is doing something entirely different—it is beginning to change us. It forces us to ask: what does it truly mean to be human when the baseline of intelligence is automated?”

Dismantling the Apex Predator Fallacy

Born in the USSR within a rigid societal value system obsessed with biological perfection, Modesta has spent two decades upending conventional narratives around disability and beauty by transforming her prosthetic limb into an iconic cultural symbol of bionic potential. In her dialogue with Rubin, she notes that AI’s rapid disruption is forcing a much-needed re-evaluation of how society measures human worth.

“What’s interesting about AI is that it’s creating a juxtaposition to what is human value for the first time at scale,” Modesta explains. “We’ve valued in the past biology, abilities with sports, and intelligence. We’re now left with having to really look at the foundation… I think that it’s super exciting because for the first time, I think we will start having a little bit more appreciation for things like nature and animals, which we’ve discarded historically because it’s not the apex predator.”

AI as an Intimate Mind Prosthetic

Rather than viewing AI with existential dread, Modesta frames the technology through her unique perspective on physical augmentation, defining AI as a “prosthetic of the mind.”

“This is a relationship question,” Modesta tells Rubin. “We have created a technology that is much closer to a musical instrument. It’s something that responds to our emotions… It’s no longer just functional. This is a vehicle for our intention, it’s a vehicle for our emotion, for our aspiration of what we would like to have for ourselves and the world.”

Modesta argues that because technology adaptation is a deeply intimate, individual process, the mystery and fear dissipate when individuals actively decide what internal cognitive gaps they want the tool to expand.

The Tyranny of Uniformity and the Rise of the “Edges”

Addressing Rubin’s concerns regarding technological conformity among youth growing up alongside AI companions, Modesta delivers an optimistic counter-narrative. She argues that the flat, homogenized outputs of current Large Language Models (LLMs) will naturally expose the absurdity of uniformity.

“We’re noticing how absurd it is for LLM systems to just kind of flatline all the information and remove all the kind of edges,” says Modesta. “If you have a resume by 20 people who all use the same models, there is no meaning. There is no differentiation. We should actually end up in a better place where for the first time somebody’s just like, ‘Well, wait a minute. What are my ideas? What is my lived experience?'”

Prototyping the Future Without Permission

Through her latest project, Metabodies—an AI-powered visual framework exploring human identity across Earth, space, and virtual environments—Modesta is using AI to democratize how future human forms are imagined. Rather than relying on corporate Hollywood or scientific pillars to dictate tomorrow’s aesthetics, she uses AI to fast-track representation across body shapes, ability, race, and gender.

Reflecting on the generations entering adulthood by 2050, Modesta notes that younger builders no longer view technology through the lens of a human-versus-machine divide. To them, the integration is fluid, and the historical barriers are dissolving. “I will be talking to somebody about why disability is actually innovation,” Modesta smiles, “and they’re like, ‘Yeah, sure. I get that.'”

Key Takeaways from the Interview:

The Redefinition of Value: Why the automation of routine intelligence will push humanity to value raw intuition, emotional depth, and ecological interconnectedness.The Cognitive Instrument: Reframing AI as a fluid, responsive medium for human intention rather than a cold threat to human agency.The Power of the Non-Standard: Why the flattening effect of AI writing and design tools will create an economic premium on distinct lived experiences and “imperfect” creative edges.Democratic World-Building: How individual creators are bypassing massive institutional gatekeepers to prototype diverse futures in digital and aerospace environments.

Rubin concludes: “Viktoria reminds us that if AI is a prosthetic for the mind, it is ultimately a vehicle for human intention. AI is not a threat to what makes us human; it is a mirror that forces us to discover it. As machines automate the routine and flatline the standard, our unique perspectives, lived experiences, and creative edges become humanity’s greatest assets.

Watch AI for a Better World: What Does It Mean to Be Human in the Age of AI?

About Viktoria Modesta

Viktoria Modesta is an internationally acclaimed British-Latvian multimedia artist, creative director, futurist, and the world’s first Bionic Pop Artist. A former MIT Media Lab Fellow, her multidisciplinary work spans bionic wearables, human-machine interaction, and aerospace research with partners including NASA JPL, the Aurelia Institute, and Mission AstroAccess. Her current project, Metabodies, uses AI to explore future human identity across real and virtual environments.

About C. M. (Cathy) Rubin

C. M. (Cathy) Rubin is Co-Founder and CEO of Planet Classroom and Founder of CMRubinWorld. A multimedia journalist, author, and regular Forbes contributor who has published over 800 interviews with global leaders, her work focuses on human-centered AI strategy, institutional innovation, and the future of global education.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-is-a-mirror-not-a-replacement-bionic-artist-viktoria-modesta-challenges-the-core-of-human-value-in-the-machine-age-302865716.html

SOURCE Planet Classroom Network

Continue Reading

Trending